Literature DB >> 30340844

A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.

Fu-Min Shang1, Jing Li2.   

Abstract

INTRODUCTION: Melanoma is the most dangerous skin cancer with high metastasis rate and mortality. Although the emergence of immunotherapy has brought hope for treatment, the mortality rate of melanoma is still increasing year by year. The underlying mechanism of melanoma tumor progression and metastasis is urgently needed to be clarified. Recently chemokines have been found to play an important role in tumor progression in addition to their immunocytochemical chemotaxis.
METHODS: In this study, human melanoma cell lines A375 and M14 were treated with SCH-527123, a small molecule antagonist of CXCR1 and CXCR2. The effects of treatment with SCH-527123 on melanoma cell proliferation, migration and invasion were evaluated in vitro by CCK-8, colony formation and transwell assays. Apoptosis was also detected by flow cytometry staining with annexin V and propidium iodide (PI). The molecular mechanisms of antagonist mediated were detected by western blot.
RESULTS: The results showed that SCH-527123 inhibited the proliferation, migration and invasion of melanoma cell lines and promoted apoptosis. The expression of CXCR1 and CXCR2 was downregulated after treatment with SCH-527123. PI3K/AKT pathway and downstream signaling were also inhibited at molecular level owing to treated with SCH-527123.
CONCLUSION: In conclusion, our study demonstrated that SCH-527123, a small-molecule antagonist for CXCR1 and CXCR2 inhibited cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.
Copyright © 2018 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  CXCR1; CXCR2; Invasion; Invasión; Melanoma; Migración; Migration; Proliferación; Proliferation; SCH-527123

Mesh:

Substances:

Year:  2018        PMID: 30340844     DOI: 10.1016/j.medcli.2018.08.006

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  6 in total

1.  Identification of four genes associated with cutaneous metastatic melanoma.

Authors:  Chen Ji; Yuming Li; Kai Yang; Yanwei Gao; Yan Sha; Dong Xiao; Xiaohong Liang; Zhongqin Cheng
Journal:  Open Med (Wars)       Date:  2020-06-11

2.  IDO Inhibitor and Gallic Acid Cross-Linked Small Molecule Drug Synergistic Treatment of Melanoma.

Authors:  Hongmei Liu; Huan Gao; Cheng Chen; Wenyu Jia; Delong Xu; Guan Jiang
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

3.  Anti-Cancer Effects of Lactobacillus plantarum L-14 Cell-Free Extract on Human Malignant Melanoma A375 Cells.

Authors:  Jaehyun Park; Mijin Kwon; Jaehoon Lee; Sangkyu Park; Jeongmin Seo; Sangho Roh
Journal:  Molecules       Date:  2020-08-26       Impact factor: 4.411

Review 4.  Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?

Authors:  Nathan Karin
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

5.  Gene Expression Profiling and Protein Analysis Reveal Suppression of the C-Myc Oncogene and Inhibition JAK/STAT and PI3K/AKT/mTOR Signaling by Thymoquinone in Acute Myeloid Leukemia Cells.

Authors:  Belal Almajali; Muhammad Farid Johan; Abdullah Saleh Al-Wajeeh; Wan Rohani Wan Taib; Imilia Ismail; Maysa Alhawamdeh; Nafe M Al-Tawarah; Wisam Nabeel Ibrahim; Futoon Abedrabbu Al-Rawashde; Hamid Ali Nagi Al-Jamal
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-03

6.  Design, Synthesis and Biological Activity Testing of Library of Sphk1 Inhibitors.

Authors:  Shuangshuang Geng; Haijiao Chen; Yan Li; Ying Li; Jingxiang Pang; Feipeng Zhang; Zhiqiang Qu; Mengjun Li; Na Liu; Qingqiang Yao; Yanling Mu; Bo Liu
Journal:  Molecules       Date:  2022-03-21       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.